SpringWorks Therapeutics, Inc. Stock price
Equities
SWTX
US85205L1070
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
50.88 USD | +1.55% | -0.41% | +40.41% |
Financials (USD)
Sales 2024 * | 86.89M | Sales 2025 * | 258M | Capitalization | 3.69B |
---|---|---|---|---|---|
Net income 2024 * | -330M | Net income 2025 * | -204M | EV / Sales 2024 * | 40.3 x |
Net cash position 2024 * | 194M | Net cash position 2025 * | 451M | EV / Sales 2025 * | 12.6 x |
P/E ratio 2024 * |
-10.7
x | P/E ratio 2025 * |
-14.2
x | Employees | 305 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.57% |
Latest transcript on SpringWorks Therapeutics, Inc.
1 day | +1.83% | ||
1 week | -0.30% | ||
Current month | +1.71% | ||
1 month | -3.78% | ||
3 months | +35.26% | ||
6 months | +111.93% | ||
Current year | +37.26% |
Managers | Title | Age | Since |
---|---|---|---|
Saqib Islam
CEO | Chief Executive Officer | 54 | 17-07-31 |
Daniel Lynch
CHM | Chairman | 66 | 17-07-31 |
Frank Perier
DFI | Director of Finance/CFO | 64 | 19-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Fuhrman
BRD | Director/Board Member | 67 | 19-07-31 |
Freda Lewis-Hall
BRD | Director/Board Member | 68 | 17-07-31 |
Carlos Alban
BRD | Director/Board Member | 61 | 22-07-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.11% | 0 M€ | 0.00% | - | |
0.10% | 0 M€ | 0.00% | - | |
0.08% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 51.15 | +2.10% | 396 542 |
24-03-27 | 50.1 | +1.83% | 502,167 |
24-03-26 | 49.2 | -0.47% | 445,069 |
24-03-25 | 49.43 | -2.68% | 322,717 |
24-03-22 | 50.79 | -1.30% | 462,722 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.26% | 3.69B | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.39% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |